Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrology 2021, 22: 284. PMID: 34419007, PMCID: PMC8379779, DOI: 10.1186/s12882-021-02491-y.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsChronic kidney diseaseEpoetin alfaDarbepoetin alfaTREAT trialTypes of ESAsNew clinical evidencePrimary care physiciansMedicare AdvantageUptake of evidenceCare physiciansAnemia treatmentClinical evidenceKidney diseasePhysician genderMedicare feeUnsafe treatmentSegmented regression approachStudy periodPhysiciansService populationConsistent changesAlfaHigher useTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply